A Multiple ascending dose clinical study evaluating combinations of an NBD1 stabilizer with galifactor SION-2222 in healthy subjects.
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Galicaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- 24 Mar 2025 New trial record
- 20 Mar 2025 According to Sionna Therapeutics media release, company plans to initiate this trial in in the second half of 2025 with topline data expected in mid-2026